- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04173611
Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers
Phase 1, Randomized, Double-Blind, Active and Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers.
Primary objective: To assess the safety and tolerability of EXPAREL® administered as a single intrathecal injection in healthy volunteers
Secondary objective: To characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of EXPAREL® administered as a single intrathecal injection in healthy volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase-1, single center, randomized, double-blind, active and placebo-controlled study in approximately 40 healthy adult subjects.
On Day 1, eligible subjects will be randomized in blocks of 5, in a ratio of 3:1:1 to receive EXPAREL® or bupivacaine or placebo (saline) injection, respectively. Starting with treatment Cohort 1, healthy volunteers will be randomized to the 3 treatment arms within cohorts. Each cohort will consist of 10 subjects (6 EXPAREL®, 2 bupivacaine and 2 placebo). In each cohort, all 10 subjects in each cohort will receive cerebrospinal fluid (CSF) taps. Within the EXPAREL® arm, subjects will be randomized 2:1 with 4 subjects undergoing CSF tap and 2 subjects not undergoing CSF tap in each cohort. Subjects who are not undergoing CSF tap, will still be injected with needles without draw of CSF to prevent subject bias. Such a randomization will allow for characterization of the complete pharmacodynamics profile of the drug without risk of drug removal in the CSF. For those subjects randomized to the EXPAREL® arm - the dose of EXPAREL® will be determined by the cohort. Starting at 1 mL (13.3 mg) for Cohort 1, the volume of EXPAREL® will be increased by 1 mL in each subsequent cohort for a maximum of 4 mL (53.2 mg). The decision to proceed to the next cohort will be made following a full review of the safety, PK, and PD (sensory and motor) data from current completed cohort(s). All subjects will remain in the EPRU for 5 days after drug administration and will be discharged on Day 6. Subjects will be instructed to return for a follow up visit on Day 9. Adverse events (AEs) and serious adverse events (SAEs) will be recorded from the time of consent through 30 days after drug administration.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adult male or female volunteers ages ≥18 and ≤50 years old.
- American Society of Anesthesiologists (ASA) physical status 1.
- Able to provide informed consent, adhere to the study schedule, and complete all study assessments.
Exclusion Criteria:
- Allergy, hypersensitivity, intolerance, or contraindication to any of the study medications for which an alternative is not named in the protocol (eg, amide-type local anesthetics, opioids, bupivacaine, non-steroidal anti-inflammatory drugs [NSAIDs], spinal anesthesia).
- Impaired renal or hepatic function (eg, serum creatinine level >2 mg/dL [176.8 μmol/L], blood urea nitrogen level >50 mg/dL [17.9 mmol/L], serum aspartate aminotransferase [AST] level >1.5 times the upper limit of normal [ULN], or serum alanine aminotransferase [ALT] level >1.5 times the ULN).
- Subjects at an increased risk for bleeding or who have a coagulation disorder (defined as platelet count less than 80,000 × 103/mm3).
- Concurrent painful physical condition that may require analgesic treatment (such as long-term, consistent use of opioids) in the post dosing period for pain and which may confound the post dosing assessments.
- Women of childbearing potential must have a documented negative pregnancy test at screening and must be confirmed on the day of drug administration. If postmenopausal, must have a documented Follicle Stimulating Hormone (FSH) test confirming menopause at screening.
- Currently pregnant, nursing, or planning to become pregnant during the study or within 30 days after completion of the study.
- Positive serology test result for Human Immunodeficiency Virus (HIV), Hepatitis B virus, or Hepatitis C virus.
- Clinically significant abnormal ECG that in the opinion of the investigator would preclude the subject from participation in the study.
- Previous participation in a Pacira study.
- History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
- Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: EXPAREL®
For those subjects randomized to EXPAREL® arm - the dose of EXPAREL® will be determined by the cohort.
Starting at 1mL (13.3mg) for cohort 1, the volume of EXPAREL® will be increased by 1 mL in each subsequent cohort for a maximum of 4mL (53.2mg).
|
Injection into the Intrathecal space.
|
ACTIVE_COMPARATOR: Bupivacaine
In each cohort, subjects randomized to the bupivacaine arm will receive 15mg of plain bupivacaine HCL (the equivalent of 13.3mg bupivacaine base) providing a 1:1 reference to the starting dose level chosen for EXPAREL®.
|
Injection into the Intrathecal space.
Other Names:
|
ACTIVE_COMPARATOR: Placebo
Subjects in the placebo arm will receive normal saline intrathecal injection
|
Injection into the Intrathecal space.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the plasma concentration-versus-time curve
Time Frame: 6-8 weeks
|
Pharmacokinetic endpoint
|
6-8 weeks
|
Maximum plasma concentration (Cmax) and time of Cmax (Tmax).
Time Frame: 6-8 weeks
|
Pharmacokinetic endpoint
|
6-8 weeks
|
The apparent terminal elimination half-life (t1/2el)
Time Frame: 6-8 weeks
|
Pharmacokinetic endpoint
|
6-8 weeks
|
Apparent clearance (CL/F)
Time Frame: 6-8 weeks
|
Pharmacokinetic endpoint
|
6-8 weeks
|
Apparent volume of distribution (Vd)
Time Frame: 6-8 weeks
|
Pharmacokinetic endpoint
|
6-8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent AEs (TEAEs) through Day 9
Time Frame: 6-8 weeks
|
Safety endpoint
|
6-8 weeks
|
Proportion of subjects who have any of neurological events
Time Frame: 6-8 weeks
|
Safety endpoint
|
6-8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average time to onset of sensory block and motor block
Time Frame: 6-8 weeks
|
Pharmacodynamic Endpoint
|
6-8 weeks
|
Average duration of sensory block and motor block
Time Frame: 6-8 weeks
|
Pharmacodynamic Endpoint
|
6-8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Donald C Manning, MD, PhD, Pacira Pharmaceuticals, Inc
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 402-C-121
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on EXPAREL
-
Pacira Pharmaceuticals, IncTerminatedPostoperative Pain ManagementUnited States
-
Pacira Pharmaceuticals, IncCompletedPostoperative Pain ManagementUnited States
-
Spectrum Health HospitalsCompletedPostoperative PainUnited States
-
Pacira Pharmaceuticals, IncCompleted
-
Rothman Institute OrthopaedicsCompletedOsteoarthritis: Joint Replacement Surgery
-
OrthoCarolina Research Institute, Inc.Pacira Pharmaceuticals, IncCompletedAnkle Arthrodesis | Hindfoot Arthrodesis | Tibitalocalceal ArthrodesisUnited States
-
Mayo ClinicSusan G. Komen Breast Cancer FoundationCompleted
-
Pacira Pharmaceuticals, IncCompletedPain Management | Spinal FusionUnited States
-
Children's Hospital of Orange CountyRecruitingPain | Anxiety | ACL Tear | Opioid MisuseUnited States